^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MCC1 TCR

    i
    Other names: MCC1 TCR, FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1
    Associations

    News

    Trials
    Company:
    Affini-T Therap, Fred Hutchinson Cancer Center, Regeneron
    Drug class:
    TCR modulator
    Related drugs:
    Associations

    News

    Trials
    17d
    ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
    P1/2, N=7, Terminated, Fred Hutchinson Cancer Center | Trial completion date: Jan 2025 --> Jan 2024 | Active, not recruiting --> Terminated; Terminated due to insufficient funding
    Trial completion date • Trial termination • Metastases • Immune cell
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
    8ms
    ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=16 --> 7 | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2024 --> Jan 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases • Immune cell
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
    1year
    ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
    P1/2, N=16, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Apr 2025 | Trial primary completion date: Dec 2025 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases • Immune cell
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR
    over2years
    ATTAC-MCC: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer (clinicaltrials.gov)
    P1/2, N=16, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Oct 2023 --> Dec 2025 | Trial primary completion date: Oct 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • MCC1 TCR
    over2years
    ATTAC-MCC: Phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade. (ASCO 2022)
    NCT03747484 is an ongoing phase I/II, open label, investigator-initiated trial (IIT) of FH-MCVA2TCR in combination with an anti-PD-(L)1 checkpoint inhibitor and an agent to upregulate MHC-I expression on tumor cells...Secondary/exploratory objectives include cellular kinetics of TCR T cells, T cell phenotype, tumor infiltration kinetics, and MHC-I expression dynamics over time. After the first 12 months, patients transition to a long-term follow-up (LTFU) study for up to 15 years as per FDA guidelines.
    Clinical • P1/2 data • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    MCC1 TCR